SXTC — China SXT Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $169.40m
- $152.11m
- $1.74m
Annual balance sheet for China SXT Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 13.3 | 15.5 | 17.4 | 12.1 | 18.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.66 | 5.53 | 1.34 | 1.35 | 1.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 23.2 | 22.5 | 19.5 | 14.2 | 21.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.79 | 1.59 | 1.27 | 0.565 | 0.355 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 34.5 | 33.5 | 29.6 | 23.1 | 21.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.6 | 17.1 | 14.5 | 8.9 | 6.01 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 18.6 | 17.1 | 14.9 | 9.2 | 6.22 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 16 | 16.4 | 14.7 | 13.9 | 15.4 |
| Total Liabilities & Shareholders' Equity | 34.5 | 33.5 | 29.6 | 23.1 | 21.7 |
| Total Common Shares Outstanding |